Overall, GRP78 can be leveraged in many diverse ways and through various approaches to improve GBM therapy, demonstrating great potential as a therapeutic target in improving first-line therapies as well as in developing alternative therapies. This evidence concerns the gene HSPA5 and glioblastoma.